This was a descriptive cross-sectional study lasting six months, from January 1 to June 30, 2025.

The population study consisted of patients referred to Mycobacterium Laboratories for tuberculosis screening, regardless of location. The study sample consisted of all patients who tested positive for tuberculosis during the first half of 2025 and for whom data were available. Sampling was therefore exhaustive for the study period. Tuberculosis cases with indeterminate resistance tests, follow-up data for patients undergoing treatment, and tuberculosis data based on microscopy were not included in the study. This is because cases of resistance identified through laboratory testing are classified as secondary resistance cases and, unlike GeneXpert, microscopy does not detect resistance.

Primary resistance is confirmed on the basis of two criteria: the patient’s lack of a clinical history of anti-tuberculosis treatment and laboratory findings. A case of primary resistance to anti-tuberculosis drugs is defined as a patient detected for the first time who presents either resistance to rifampicin or multidrug resistance and who has never been on anti-tuberculosis treatment, with supporting evidence (not registered in the tuberculosis register or having no clinical record).

A data collection form was prepared in advance for the purpose of gathering data. This form lists the variables to be recorded as part of the study. The data source was the Mycobacteria laboratories’ database. The Access template for the form is made available to laboratories involved in the National Tuberculosis Control Programme. Duplicate data consisted of test errors caused by power cuts (the word “error” displayed on the screen instead of a negative or positive result). These erroneous data were excluded from the analysis as the patient must return for a second test. Data cleaning also addressed input errors for certain data.

The variables in the study were age, sex, place of residence (district or region), screening status (negative or positive), degree of test positivity (very low, low, high, very high), resistance to anti-tuberculosis drugs (yes or no), and type of resistance (resistance to rifampicin or multidrug resistance).

In the laboratory, the analysis technique used was the GeneXpert test. GeneXpert is a molecular biology technique that enables rapid detection of Mycobacterium tuberculosis DNA and rifampicin resistance. It is a semi-quantitative automated test based on real-time semi-nested amplification of the core region of the rpoB locus for the diagnosis of TB and for the detection of genetic mutations associated with rifampicin resistance. It also increases the detection rate of Mycobacterium tuberculosis and enables early screening for rifampicin resistance. Under the hood, carefully unscrew the spittoon. From direct sputum: Take 2 vol ml of Sample Reagent and 1 vol of sputum in a 15 ml Falcon tube. From the decontaminated pellet, take 1.5 ml of sample reagent and 0.5 ml of pellet. Shake the mixture and leave it at room temperature for 10 minutes. Shake again and leave for 5 minutes. Remove the cartridge from its packaging and open the cartridge cover. Use the pipette to draw up the liquefied sample. Transfer 2 ml of the sample into the cartridge chamber. Start the test within 30 minutes. The result is generated from the measured fluorescence signals and integrated calculation algorithms. The response appears on the screen in less than 2 hours. The result is semi-quantitative for the presence of M. tuberculosis complex DNA. The result indicates whether or not rifampicin resistance has been detected.

The collected data were entered into Excel 2016 and analyzed using Epi Info version 7 software. The number and frequency of each variable in the study were determined. The tuberculosis prevalence rate was calculated as the ratio of the number of positive tests to the total number of patients screened. The prevalence rate of resistance was determined as the number of cases of resistance divided by the total number of positive tuberculosis cases. These calculated rates were expressed as percentages. Karl Pearson’s chi-square test, significant for a p-value of less than 5%, was used to highlight the association between tuberculosis and the study variables. The odds ratio (OR) and adjusted odds ratio (ORa) were determined by bivariate or multivariate analysis and logistic regression, respectively. We coded the variables using numerical codes in accordance with the requirements for logistic regression.

According to Table 1, 12,112 patients aged between 4 months and 100 years were registered between January and June 2025 in the Central African Republic. The median age was 35 ± 18 years and the most common age was 40 years. The most represented age group was 15 to 49 years old, with 7536 participants and 2144 positive cases. The male-to-female ratio was 1.28. The overall prevalence of primary tuberculosis resistance was 6.07%. The prevalence of single-drug resistant tuberculosis was 5.67% and that of multi-drug resistant tuberculosis was 0.41%. Resistance to rifampicin alone accounted for 93.10% of resistant cases. This primary resistance was predominant in the 15 - 49 age group with N = 135 and in men with N = 121. Table 1 shows the distribution of tuberculosis cases by month, age, and sex.

Table 1. Distribution of tuberculosis cases by month, age, and sex.

According to Figure 1, cases of primary resistance gradually decreased in January. From February onwards, this rate increased gradually until May, when it peaked at 8.7%, before decreasing in June to 7.15%. The highest prevalence of resistance was in June, with 48 cases, or 8.7%. Figure 1 shows the distribution of resistant tuberculosis by month.

Figure 1. Distribution of drug-resistant tuberculosis by month.

According to Table 2, 2862 positive cases were recorded, including 174 cases of drug-resistant tuberculosis, of which 162 were resistant to first-line drugs and 12 were multidrug-resistant. The highest prevalence of first-line resistance cases was found in the Bimbo health district with 11.8%, followed by the Nana Gribizi health district with 11.5% and the Kemo health district with 11.1%. Cases of single resistance (56.17%) and multi-resistance (100%) were most prevalent in the Bangui 1 health district. Table 2 shows the distribution of tuberculosis cases and resistance by district and health region.

Table 2. Distribution of drug-resistant tuberculosis cases by place of residence.

HR = Health region and NR = Not received.

The highest number of cases of tuberculosis resistant to anti-tuberculosis drugs was found in Health Region No. 7 of the country with 79 cases, followed by Health Region No. 1 with 30 cases. Figure 2 shows the distribution of tuberculosis cases and resistance by region.

Figure 2. Distribution of tuberculosis cases by region.

Cases of primary resistance to anti-tuberculosis drugs were more common in sputum samples (93.67%) and in patients with a high bacterial load (33.33%). These data are presented in Table 3.

Table 3. Distribution of primary resistance by type.

Variables associated with the risk of drug-resistant tuberculosis.

Month (p = 0.03), sex (0.03), place of residence (p = 0.04), pulmonary location (0.02), and bacterial load (0.01) were variables significantly associated with resistance. The risk of developing resistant tuberculosis was 3.50 times higher in patients with pulmonary tuberculosis (adjusted OR = 3.50, CI = [1.07 - 8.15]). These data are presented in Table 4.

Table 4. Presents the variables associated with the risk of resistance by logistic regression.

Low load = very low + low + medium; High load = high + very high.

Tuberculosis remains the leading cause of morbidity and mortality in the Central African Republic despite numerous control programs. In addition to the complications of this disease caused by HIV/AIDS, there is now the phenomenon of Mycobacterium tuberculosis resistance to anti-tuberculosis drugs. During the first half of 2025, we recorded 2862 cases of tuberculosis in the seven health regions of the CAR, including 174 cases of resistance. In terms of proportion, these cases of resistance were most prevalent in June with 26.85% and May with 45 cases, in RS7, which includes the DS of Bangui 1, 2, and 3 (93 cases), among children aged 15 to 49 (137 cases), men (122 cases), sputum samples (162) and patients with a high bacterial load (58). The study samples were more numerous in June with 671 cases and May with 517 cases. In CAR, the rainy season lasts from April to October, creating conditions conducive to the survival of the bacillus in the environment due to humidity. The population, and indeed the cases of tuberculosis, were predominantly among young adults (n = 2142). In Africa in general, and in CAR in particular, young people predominate. This predominance among young adults is consistent with previous studies conducted in CAR [4]-[7]. The predominance of males is consistent with data from other studies conducted in the CAR and elsewhere [4]-[12][14]-[16]. This could be the result of differences in exposure between men and women in terms of their roles in society. Men are often involved in several sectors of activity, which could increase their exposure to the risk of disease [14]. Sputum samples were the predominant sample type among patients undergoing screening; this explains the high number of tuberculosis cases, including cases of resistance, for this type of sample. Added to this is the fact that pulmonary tuberculosis is the most common form of the disease and the form most likely to spread. The predominance of pulmonary tuberculosis in our study is consistent with studies conducted in the Central African Republic and elsewhere [17]-[19].

Secondary resistance can develop into what is known as primary resistance. This can be explained by the context of treatment for each patient. When tuberculosis treatment is poorly designed or poorly followed by the patient, it can lead to the selection of resistant mutants. This is known as secondary resistance or resistance acquired during treatment. Tuberculosis patients carrying a resistant strain can infect those around them, who will develop tuberculosis with bacilli that are resistant from the outset. This is known as primary resistance. The increase in cases of primary resistance is proportional to that of secondary resistance when conditions are favorable for the spread of bacilli [14]. This increase reflects the cases of primary resistance already reported in the CAR. The prevalence of primary resistance reported in our series was 6.07%. This is higher than that reported in studies by Farra et al. in CAR (4.1%) and Burkina Faso (12.4%) [11][15]. In contrast, this prevalence is lower than that reported in studies conducted by Natelao et al. (7.69%), Bamozouré et al. (6.15%) in the Central African Republic, and Walbang et al. in Chad [12][13][16]. The prevalence of primary resistance also reflects the reservoir of resistant strains among cases that have already been treated [17]. The natural resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs is rare, and the selection of drug-resistant strains is almost always the result of inadequate treatment. The probability that a mutation will lead to drug resistance is directly proportional to the size of the bacterial population in the patient. The high bacterial load reported in this study was significantly associated with resistance to anti-tuberculosis drugs. It is therefore most often monotherapy or inadequate treatment that has allowed the emergence of MDR strains [17].

Following the emergence of multi-resistant strains in several countries around the world, resistance to anti-tuberculosis drugs poses a threat to tuberculosis control programs [18]. A WHO study of 17,690 tuberculosis cases in 49 countries between 2020 and 2024 revealed that 20% of cases were MDR-TB. In our study, MDR-TB accounted for 6.07% of new cases. This proportion is below the critical threshold set by the WHO at 10% [17]. When standardized chemotherapy programs comply with WHO recommendations, the prevalence of primary MDR-TB is less than 3% [17]. Multi-drug resistance rates higher than our data have been reported in Rwanda (7%) and in Henan Province (11%) in China [18][19]. These differences could be explained by the high rates of TB in these countries. In contrast, lower rates have been observed in Madagascar (0.2%) and Kenya (0.54%) [20][21]. The proportion of secondary MDR-TB reported in our study was 37.5% (3/8). The emergence of multidrug resistance is a major threat, both at the individual level and for the national tuberculosis control program. Patients harboring these strains are extremely difficult to treat and require much more expensive and toxic treatments [22]. As expected, the risk of resistance is much higher when the patient has already received anti-TB treatment in the past, which shows how important it is to know the patient’s history [2][3]. These observations show how important it is to know the country of birth of patients in order to interpret the results of resistance surveillance, as recommended by the WHO. Finally, the cases of multidrug resistance reported here are likely to be underestimated (12 cases of multidrug resistance compared to 162 cases of monoresistance). These are cases of multidrug resistance detected only in the capital by the two reference laboratories that use the GeneXpert 10-color test. This is because 32 districts do not use the GeneXpert 10-color test, which has the ability to detect monoresistance, multidrug resistance, and ultraresistance. Therapeutic failure could occur if another anti-tuberculosis drug prescribed in addition to rifampicin for cases of monoresistance is not the most appropriate (due to undetected resistance). The GeneXpert ten-color test needs to be rolled out to all districts in the country to enable wider diagnosis of cases of resistance. In fact, access to molecular testing (GeneXpert) is the same for laboratories in district and regional hospitals across the CAR. These laboratories all receive support from the Global Fund to Fight HIV, Tuberculosis and Malaria. The difference is that these two laboratories have been provided with this model of GeneXpert (ten-colour) by the Global Fund for specific reasons. The Pasteur Institute in Bangui is the Reference Laboratory for tuberculosis in the CAR, and the National Clinical Biology Laboratory is the national reference laboratory. Furthermore, the transport of samples in rural areas is secure, and there are no security-related constraints for tuberculosis. It should also be noted that regional comparisons may reflect testing coverage rather than genuine differences in incidence. The performance of GeneXpert in the screening for tuberculosis has been demonstrated in a number of studies. This relates to the test’s sensitivity, its specificity (as it does not detect atypical mycobacteria), its speed (in contrast to culture), and its ability to detect cases of resistance to anti-tuberculosis drugs [23][24]. Added to this is its significant contribution to the surveillance of cases of drug-resistant tuberculosis [25]-[27]. Implementing certain measures will enable better control of primary tuberculosis resistance. These measures focus on transmission and, more specifically, the rapid detection of drug-resistant TB, the prevention of infections in clinics, contact tracing and the provision of rapid, effective treatment. Secondary resistance is the direct consequence of poor management. Early diagnosis of resistance allows for the rapid implementation of appropriate treatment and improves the patient’s prognosis while reducing the risk of transmission of resistant strains, which leads to primary resistance. To prevent the occurrence of primary resistance, the transmission of mutant and drug-resistant bacilli must be interrupted. In addition to treatment history, which takes into account interruption of anti-tuberculosis treatment and treatment abandonment, cases of self-medication should also be reported. According to the policy of the Ministry of Health and Population, anti-tuberculosis treatment is free of charge in CAR. Anti-tuberculosis drugs are not sold on the market. First-line anti-tuberculosis drugs such as rifampicin, isoniazid, and ethambutol are not recommended for medical prescription for other diseases in CAR. This is to prevent the development of resistance to these molecules. However, these molecules are available at certain street drug outlets. The use of anti-tuberculosis drugs is not limited to tuberculosis, but also extends to other common diseases in the community (wounds, typhoid fever, COVID-19, etc.). The Central African government has just taken measures to ban the sale of drugs on the street. This initiative will enable the Ministry of Health and Population to better monitor trends in resistance to anti-tuberculosis drugs.